Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

2.

Report: Breast cancer mortality continues three decade decline, but steeper increases in incidence for some women

3.

PSA Screening May Modestly Curb Prostate Cancer Deaths

4.

Improved end-of-life conversations for cancer patients are identified by a new study.

5.

Enhanced CAR T cell therapy offers new strategy for lymphoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot